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SERUM GROWTH DIFFERENTIATION FACTOR-15 LEVELS IN 
PATIENTS WITH ULCERATIVE COLITIS 
 
BACKGROUND 
Hepcidin is the central regulator of iron homeostasis. Previous work 
done in the Department of Biochemistry, CMC, Vellore, has shown 
that serum hepcidin levels were decreased in patients with ulcerative 
colitis. Growth differentiation factor-15 (GDF-15) is a known negative 
regulator of hepcidin. 
 
AIM  
The aim of the study was to test the hypothesis that serum GDF-15 
levels may be increased in patients with ulcerative colitis (UC), thus 
accounting for decreased levels of hepcidin in such patients and to 
determine whether it correlates  with hemoglobin and markers of 
iron status (serum iron and ferritin). 
 
MATERIALS AND METHODS  
Twenty patients diagnosed with UC, who were not on iron 
supplements or erythropoietin therapy, served as cases. Twenty age 
and gender-matched non-anaemic patients, who underwent upper 
gastrointestinal endoscopy for evaluation of dyspepsia and who were 
found to have no endoscopic abnormalities served as controls. A 
blood sample collected from each subject, after obtaining informed 
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consent, was used to estimate haematological parameters and serum 
levels of GDF-15, iron, ferritin, and C-reactive protein (CRP).  
                                    
 
RESULTS 
Serum GDF-15 levels were significantly higher (912.8 ± 430 pg/ml vs  
623.7 ± 285 pg/ml) and hemoglobin levels significantly lower in 
patients with UC, when compared to control subjects.  Levels of 
GDF-15 and haemoglobin showed a negative correlation with one 
another.   
 
CONCLUSION 
Serum GDF-15 levels were increased in patients with UC. Such 
raised levels may account for decreased hepcidin levels that have 
been observed in such patients.  
 
 
Key words: GDF-15, ulcerative colitis, anaemia, iron, hepcidin 
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INTRODUCTION 
 
Iron is a transitional metal, which is necessary for heme synthesis 
and a number of other biological functions. It is a redox-active metal 
and has the ability to accept or donate electrons. Due to this 
property, it plays an important role in processes like generation of 
energy by the electron transport chain and helps in metabolism, by 
serving as a cofactor for various enzymes. However, iron can also be 
harmful. When present in excess, it can participate in Fenton 
reactions leading to free radical formation, which leads to oxidative 
stress in the cell. Therefore, iron levels have to be constantly 
maintained at a steady state (Wessling-Resnick, 2014).  
 
Iron distribution in the body: 
 
An adult male has about 3.8 grams of iron and adult females about 
2.3 grams (Wessling-Resnick, 2014).  Hemoglobin contains about 
67% of the total iron in the body; 27% is present as ferritin and 
hemosiderrin, 3.7% as myoglobin and only 0.08% of it is in 
circulation bound to transferrin (Higgins et al, 2012). The major iron 
consumer in the body is the bone marrow erythroid precursors, 
where it is utilized for hemoglobin synthesis. About 20-25mg of iron 
is utilized for this process in a day. There is no regulated excretory 
route for iron. About 1-2mg is lost through desquamation of 
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epithelium from mucosal membrane, skin and through menstrual 
blood loss in females (Adamson, 2011). 
 
Iron needs of the body are met by 2 processes:  iron recycling and 
intestinal absorption. About 20-25mg of iron is recycled through 
erythrophagocytosis by macrophages of the reticuloendothelial 
system (Kautz and Nemeth ,2014). Only about 1-2 mg of iron enters 
the body through intestinal absorption. However, this process is 
highly regulated.  
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Figure 1: Depiction of iron distribution in body 
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INTESTINAL IRON ABSORPTION 
 
The amount of iron absorbed by the intestine is small, when 
compared to iron recycled by macrophages, in meeting iron needs. 
However, it is the only means for iron entry into body and is 
regulated by iron status of body.  Intestinal absorption therefore 
plays a major role in maintaining iron homeostasis (Wessling-
Resnick, 2014). 
 
Iron exists as heme and non-heme iron in diet. Heme iron is present 
mainly in non-vegetarian diet and its bioavailability is high compared 
to non-heme iron (Wessling-Resnick, 2014). About 10-20mg of iron is 
present in human diet, of which only 1-2 mg is absorbed, mainly in 
the proximal duodenum (Adamson, 2011). 
 
Absorption of non-heme iron: 
 
Non-heme iron in the diet exists in the ferric form, which has to be 
converted to the ferrous form before being absorbed (Wollenberg and 
Rummel 1987). In the duodenum, ferric iron is converted to ferrous 
iron by duodenal cytochrome b (Dcyt b) (McKie et al. 2001). Once 
reduced by Dcytb, ferrous iron is transported across the apical 
membrane into the enterocyte by divalent metal transporter 1(DMT-
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1) (Gunshin et al. 1997). In the enterocyte, ferrous iron enters the 
labile iron pool from where it is transported out into circulation by 
ferroportin or stored within the cell as ferritin (Evstatiev and Gasche 
2011).  
 
Dcytb is a transmembrane ferric reductase expressed in the brush 
border of the proximal duodenum (McKie et al. 2001). It is an 
ascorbate-dependent ferric reductase, where cytosolic ascorbate acts 
as an electron donor, for luminal reduction of iron (Su and Asard 
2006). Its expression is increased in iron-deficient states (McKie et al. 
2001). The observation that Dcytb knockout mice did not develop 
iron deficiency, questioned the necessity of Dcytb in iron absorption 
(Gunshin et al. 2005). Normal iron status  in these mice was 
attributed to the  presence of  reducing substances in diet, which 
may play role in reduction of dietary ferric iron under normal 
conditions (Choi et al. 2012). However, a reduction in splenic iron 
was observed in Dcytb knockout mice, when exposed  to hypoxia 
(Choi et al. 2012). The reduction was attributed to increased 
mobilization of tissue iron to meet increased iron requirement due to 
hypoxia, as increase of duodenal absorption was not possible (Choi 
et al. 2012). This observation suggested that Dcytb is necessary in 
conditions with increased iron requirement, where its expression is 
up-regulated. 
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DMT1 
Divalent metal transporter 1(DMT1) is also known as DCT1, NRAMP 
2, SLC11A2. It belongs to natural resistance associated macrophage 
protein (NRAMP) family. DMT1 is a membrane-spanning protein 
located in the apical membrane of enterocytes. Expression of DMT1 
is high in the proximal duodenum, where it is mainly involved in Fe2+ 
absorption (Gunshin et al. 1997). Transport of Fe2+ by DMT1 is 
coupled with co-transport of a proton. It  is also transports  other 
divalent metal ions like Zn2+, Cu2+, Mn2+, Co2+, Cd2+, Ni2+ and 
Pb2+(Gunshin et al. 1997). 
 
DMT1 is also expressed in erythrocyte membranes and has a role in 
iron uptake. Autosomal recessive microcytic hypochromic anemia 
was observed in Belgrade (b) rat and microcytic anemia (mk) mice. 
Both these animal models were found to have similar missense 
mutations in DMT1, where glycine is substituted for arginine at 185th 
position in the polypeptide chain (Fleming et al. 1997; Fleming et al. 
1998). This mutation in DMT1 decreased intestinal iron absorption 
and also erythroid iron uptake, which explains the phenotype 
observed in these animals (Fleming et al. 1997; Fleming et al. 1998). 
This finding signifies the important role played by DMT1 in intestinal 
iron absorption. 
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Absorption of heme iron:  
 
Proteolytic degradation of heme proteins by digestive enzymes in the 
intestine separates heme from the polypeptide. Heme is then  
absorbed by putative heme transporters in the apical membrane of 
the enterocyte (Shayeghi et al. 2005). In the cytosol, Fe2+ is released 
from heme by heme oxygenase-1 (HO1) (Raffin et al. 1974). The fate 
of Fe2+ released from heme is similar to that of non-heme iron from 
the diet.  
 
Efflux of iron into circulation from enterocytes: 
 
Iron (Fe2+) from enterocytes, enters the circulation with the help of 
iron export protein, ferroportin.  Ferroportin is a transmembrane 
protein; it is also called SLC 40A1, IREG1 or MTP 1. It is highly 
expressed in the proximal intestine, macrophages, placenta and to 
lower extent in hepatocytes (McKie et al. 2000; Abboud and Haile, 
2000; Donovan et al. 2000). In the proximal duodenum, it is localized 
to the basolateral membrane of enterocytes (McKie et al. 2000). It 
plays a major role in iron absorption, by transporting Fe2+ across the 
basolateral membrane (Donovan et al. 2005). Expression of 
ferroportin is regulated by iron status and is increased by iron 
deficiency and hypoxia (Donovan et al. 2005). Fe2+ transported 
across the basolateral membrane by ferroportin, is oxidized by 
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hephaestin, before it is released into circulation. SLA (sex-linked 
anemia) mice with a mutation in hephaestin, manifests with 
moderate to severe microcytic anemia (Vulpe et al. 1999). In SLA 
mice, luminal uptake of iron into enterocyte was normal, but release 
of iron into circulation was impaired due to the mutation (Vulpe et 
al. 1999). This observation signifies the essential role of hephaestin, 
a multicopper ferroxidase, in release of absorbed iron into circulation 
(Vulpe et al. 1999). 
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Figure 2: Proteins involved in intestinal iron absorption  
 
 
 
 
Source: (Evstatiev and Gasche 2011) 
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IRON RECYCLING 
 
Major iron needs of body are met from iron recycling by 
macrophages. Senescent RBCs undergo the process of 
erythrophagocytosis in the reticuloendothelial system. During this 
process, RBCs are phagocytosed by macrophages. In the 
phagolysosome,  ferrous iron is released from heme by the action of 
HO-1 (Poss and Tonegawa 1997) and is transported into cytoplasm 
by NRAMP1 (natural resistance associated macrophages protein 1) 
(Tabuchi et al, 2000). Ferrous iron either enters the labile iron pool 
from where it is transported out of the macrophage by ferroportin 
(Donovan et al. 2005) or is stored as ferritin. Ceruloplasmin in blood 
oxidizes ferrous iron to the ferric form (Harris et al. 1999), which 
then binds to transferrin in circulation. 
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Figure 3: Iron recycling by macrophages 
 
 
Source :(Kemna et al. 2008) 
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IRON IN CIRCULATION 
 
Iron absorbed from the intestine or released from macrophage enters 
the circulation in the ferric form. As ferric iron is insoluble, it is 
transported in circulation bound to apo-transferrin (Baker 1994). 
Apo-transferrin is a bi-lobed glycoprotein with 2 iron-binding sites, 
that can bind ferric iron and the binding is reversible. At a given 
point of time, about 30-40% of binding sites are occupied by iron 
(transferrin saturation). Saturation of transferrin is utilized clinically 
in assessing iron status of the body (Higgins 2012). 
 
 In conditions with iron overload, increased iron in circulation 
exceeds the capacity of transferrin to bind iron (Barisani et al. 1995). 
The unbound iron that accumulates in circulation is known as non-
transferrin bound iron (NTBI). The process of NTBI uptake by the cell 
is not well understood. L-type voltage dependent calcium channel 
(LVDCC) is shown to be involved in the NTBI uptake by myocardium, 
thus accounting for cardiomyopathy observed in iron overload (Oudit 
et al. 2003). DMT1 and Zip14 mediate NTBI uptake by the 
hepatocytes. 
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PERIPHERAL UPTAKE OF IRON 
 
 
Cellular uptake of iron occurs through receptor-mediated 
endocytosis. Transferrin receptors on the cell surface binds to holo-
transferrin and the whole complex is endocytosed. There are 2 types 
of transferrin receptors (TfR) - TfR1 and TfR2 (Kawabata et al. 
1999).TfR1 is expressed in all cells, while TfR2 is expressed in 
hepatocytes and erythroblasts. TfR1 is the receptor involved in iron 
uptake into a cell. Targeted disruption of TfR1 in mice was 
associated with severe anemia (Levy et al. 1999), while  mutation in 
TfR2 is mainly associated with iron overload (Roetto et al. 2002). 
 
The major portion of iron is utilized for erythropoiesis; two-thirds of 
iron in the body is directed towards this process. Transferrin binds to 
TfR1 and the complex is internalized by endocytosis. The endosome 
is acidified by Na+-H+ ATPase. The acidic pH causes dissociation of 
ferric iron from transferrin. The ferric iron is reduced to its ferrous 
form by the six transmembrane epithelial antigen of prostate 3 
(STEAP3) (Ohgami et al 2005). Ferrous iron is carried out of 
endosome by DMT1 (Fleming et al, 1998). The apo-transferrin and 
transferrin receptors in the endosome are then transported back to 
the plasma membrane (Klausner et al, 1983). 
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The iron thus taken up into the cell is diverted to meet cellular iron 
needs. In erythroid progenitor cells, most of the iron from labile pool 
is taken up by mitochondrial mitofferin for synthesis of heme 
(Ponka,1997). Mitoferrin has been found to be the chief iron 
transport protein in mitochondria, by Shaw et al, who observed that 
mutations in mitofferin was associated with severe hypochromic 
anemia (Shaw et al, 2006). 
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Figure 4: Transferrin cycle 
 
 
 
 
 
 
Source: (Andrews, 2000) 
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FERRITIN: STORAGE FORM OF IRON 
   
Once the cellular iron needs are met, the excess iron in the labile 
pool is sequestered into ferritin. Ferritin is a hetero-polymer made up 
of heavy (H) and light (L) chains and is ubiquitously expressed in all 
cells of the body. It has 24 protein subunits, which form a shell-like 
structure around the core containing iron in a ferrihydrate form. 
Ferrous iron is taken up and oxidized by a catalytic site on the H 
chain of ferritin (Lawson et al. 1989). Iron in ferritin is easily 
mobilized as and when the cellular need arises (Higgins, et al, 2011).  
 
Ferritin is also present in serum in small quantities, the source of 
which is not known. Serum ferritin is mainly made up of L chains, 
which may be glycated and is poor in iron content (Santambrogio et 
al. 1987) and is said to reflect iron stores of the body (Lipschitz, 
Cook, and Finch 1974). Its levels are reduced in iron deficiency 
anemia. But it is not a reliable marker of iron deficiency, if it is 
associated with acute or chronic inflammation, in which case ferritin 
levels are increased (Lipschitz, et al 1974).  
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INTRACELLULAR IRON HOMEOSTASIS 
 
 
Cellular iron content is maintained by regulating various proteins 
involved in iron storage and utilization and transporters of iron 
across the cell membrane. These proteins are regulated post-
transcriptionally, at the level of translation, by altering the stability 
of mRNA or repressing its translation (Hentze et al. 1987). The mRNA 
of these proteins contains hair-pin loop-like domains in the 5’ or 
3’untranslated region (UTR) known as iron-responsive elements 
(IRE). Ferritin (H and L chain) (Leibold and Munro,1988), ferroportin, 
erythroid 5-aminolevulinic acid synthase (Cox et al. 1991) and  
mitochondrial aconitase have IRE in the 5’ end (Zheng et al. 1992), 
while IRE of  transferrin receptor1 is in the 3’ end. These IREs 
provides binding sites for iron-responsive proteins (IRPs) (Rouault et 
al. 1990; Anderson et al. 2012). 
 
IRPs are of two types - IRP1 and IRP2. IRP1 is a cytosolic protein 
with dual function. It is active in the absence of iron and binds to the 
IRE of mRNA. It is inactive in the presence of iron and functions as 
cytosolic aconitase (Zheng et al. 1992). Binding of IRPs to IRE in the 
5’ end of mRNA inhibits its translation (translational arrest) and 
binding to IRE in 3’ end promotes translation, as it stabilizes mRNA 
by preventing its degradation. IRP2 is active in the absence of iron. 
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In the presence of iron, it is rapidly ubiquitinated and proteasomally 
degraded.  
 
When cells have sufficient iron, iron-sulphur clusters are formed, 
which bind to IRP1 and inhibit it from binding to the IRE. This 
promotes translation of ferritin and ferroportin, which have IRE at 
the 5’ UTR and decreases translation of transferrin receptor 1 which 
has IRE at the 3’ UTR, by increasing mRNA degradation (Pantopoulos 
2004). 
 
When the iron content of the cell is low, iron-sulphur clusters are not 
formed. IRP1 is activated and binds to the IREs. Binding of IRP to 5’ 
IRE represses translation. Therefore, translation of ferritin (H and L 
chain), ferroportin, erythroid 5-aminolevulinic acid synthase and 
mitochondrial aconitase are reduced. Binding of IRP1 to 3’ IRE 
stabilizes the mRNA and promotes translation of transferrin receptor 
1. This promotes iron uptake by the cells and decreases the 
translation of proteins involved in iron storage and utilization 
(Anderson et al. 2012). 
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Figure 5: Regulation of cellular iron content by Iron Responsive 
proteins 
. 
 
Source: (Anderson et al. 2012) 
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SYSTEMIC IRON REGULATION 
 
Systemic iron levels are maintained by regulating its entry into the 
circulation. This is done through regulation of intestinal iron 
absorption and release of iron from reticuloendothelial macrophages 
and hepatocytes.  As there are no physiological means of iron 
excretion from the body, iron homeostasis is tightly regulated at the 
level of intestinal absorption. Hepcidin is the principal iron-regulatory 
peptide involved in systemic iron regulation. 
 
Hepcidin was discovered in human blood ultra-filtrate, as a result of 
a search for disulphide-rich antimicrobial peptides. It was found to 
be highly expressed in the liver and was therefore called LEAP 1 
(liver-expressed antimicrobial peptide) (Krause et al. 2000). 
Subsequently it was named hepcidin by Park et al, who isolated it 
from urine (Park et al. 2001). Hepcidin is a 25-amino acid-containing 
peptide, with 8 cysteine (~60%) residues.  
 
The observation that iron overload in mice induced hepcidin 
expression provided the first link between hepcidin and iron 
metabolism (Pigeon et al. 2001). Further, it was shown that upstream 
stimulatory factor 2 (USF-2) knockout mice were hepcidin-deficient 
as well and developed iron overload in hepatocytes and  low iron 
levels in macrophages (Nicolas et al. 2001). This was similar to 
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findings in HFE knockout mice and other hemochromatosis mouse 
models (Nicolas et al. 2001).On the other hand, transgenic mice 
models with hepcidin over-expression developed severe iron 
deficiency anemia (Nicolas et al. 2001). Some types of juvenile 
hemochromatosis patients had mutations in hepcidin (Roetto et al. 
2003). Low hepcidin levels were observed in hemochromatosis 
patients with mutation in HFE and TfR2 (Bridle et al. 2003; Nemeth 
et al. 2005; Papanikolaou et al. 2004). These findings highlight the 
role of hepcidin in the maintenance of iron levels in the body. 
 
Hepcidin regulates iron levels by acting on ferroportin, the only 
known iron export protein expressed mainly in macrophages, 
enterocytes and syncytiotrophoblast in placenta (McKie et al. 2000; 
Abboud and Haile, 2000; Donovan et al. 2000). It post-translationally 
regulates ferroportin levels by internalization and degradation of the 
protein, thus reducing its numbers in the membrane (Nemeth et al. 
2004). Low hepcidin levels were associated with increased expression 
of iron-related protein like ferroportin (Viatte et al. 2005).  
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REGULATION OF HEPCIDIN SYNTHESIS 
 
 Hepcidin is regulated mainly at the level of transcription by factors 
such as iron status of the body, hypoxia, erythroid activity and 
inflammation. Low iron levels, increased erythropoiesis, and hypoxia 
act as negative regulators, thus decreasing hepcidin, thereby 
increasing iron absorption and release. Increased iron levels, and 
inflammation act as a positive regulators, thereby decreasing iron 
absorption and lowering body iron levels (Hentze et al. 2010). 
Hepcidin is a type 2 acute phase protein. Inflammation up-regulates 
its  transcription  via cytokines like  IL-6, which decreases iron 
absorption and also promotes sequestration of iron in macrophages, 
whereas tumor necrosis alpha can decrease its expression (Nemeth 
2003). 
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  REGULATION BY IRON LEVELS        
 
Under physiological conditions hepcidin levels are chiefly regulated 
by iron availability. Two main signaling pathways are involved: 
1) Hfe-TfR2 (HFE-transferrin receptor 2) pathway 
2) HJV-BMP (hemojuvelin–bone morphogenic protein pathway) 
signaling 
  
1) Hfe-TfR2 signaling: 
 
Most of our understanding of Hfe-TfR2 pathway in regulation of iron 
levels via hepcidin is based on the observation of mutations 
associated with iron dysregulation in hemochromatosis. The proteins 
involved in this pathway are Hfe and transferrin receptor 2. 
Mutations of these proteins  were observed in patients with 
hemochromatosis (Feder et al. 1996; Roetto et al. 2002), who were 
found to have low levels of hepcidin associated with  iron overload. 
Iron overload in these patients was attributed to a low level of 
hepcidin, leading to increased iron absorption (Bridle et al. 2003; 
Nemeth et al. 2005; Papanikolaou et al. 2004). Further, it was shown 
by Nicolas et al that a mouse model produced by crossing  Hfe-/- and 
hepcidin over-expressing transgenic mice, constitutively expressed 
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hepcidin and prevented iron overload, in contrast to that seen Hfe-/- 
mice  (Nicolas et al. 2003). 
 
Hfe is a transmembrane protein, which is highly expressed in 
hepatocytes (Zhang et al. 2004). It is structurally similar to major 
histocompatibility complex (MHC) class I molecules with α1,α2, α3 
and α4  associated with β2 micro globulin (Feder et al. 1997). Alpha 1 
and 2 domains interact with the ecto-domain of transferrin receptor 
1 (TfR1) and form a complex (Bennett, Lebrón, and Bjorkman 2000). 
As binding site of Hfe and Tf-Fe (holo-transferrin) overlap, TfR1 
affinity towards Tf-Fe is decreased, due to formation of a complex 
(Feder et al. 1998).  
 
Hfe can also bind to TfR2, which has ~ 45% homology with TfR1 and 
is highly expressed in hepatocytes (Kawabata et al. 1999). Hfe 
displaced from TfR1 by Tf-Fe binds to TfR2. Unlike TfR1, which is 
involved in cellular iron uptake and whose expression is regulated by 
cellular status, TfR2 is not necessary for cellular  iron uptake, and 
its membrane stability is increased by ligand (Tf-Fe) binding (Robb 
and Wessling-Resnick 2004). TfR2 binding differs from TfR1 in that it 
can bind to both Hfe and holo-transferrin simultaneously (Chen et al. 
2007; Gao et al. 2009). 
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Mouse models with mutation in TfR1, which increase its binding 
affinity to the Hfe had decreased hepcidin levels and iron overload 
comparable with that of hemochromatosis. A mouse model, with a 
TfR1 mutation decreasing its binding affinity to Hfe, had increased 
hepcidin and iron deficiency. Based on these findings, Schmidt et al 
suggested that TfR1 sequesters Hfe. Increased concentration of holo-
transferrin displaces Hfe from TfR1 and promotes its interaction with 
TfR2, which leads to hepcidin transcription (Schmidt et al. 2008). 
Further, this model was supported by the finding that increase in 
hepcidin levels by holotransferrin depends on interaction of Hfe and 
TfR2 in cell membranes of hepatocytes (Gao et al. 2010). 
 
2) HJV-BMP (hemojuvelin–bone morphogenic protein 
pathway) signaling 
 
 
BMP belongs to the transforming growth factor (TGF) –β super 
family, which has diverse functions like cell proliferation, 
differentiation and cell signaling. They are said to have autocrine and 
paracrine actions. Binding of BMPs to its receptor complex involves 
dimerization of type I and II BMP (serine/threonine kinase) receptor 
on the cell membrane, with help of a co-receptor. This binding 
induces phosphorylation of receptor-regulated SMAD (R-SMAD), 
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which then complexes with co-SMAD to form a transcription factor 
that favors transcription (Shi and Massagué 2003).  
 
 
 BMP/HJV/SMAD pathway is involved in hepcidin transcription in 
hepatocytes. BMP6 is the main ligand (Andriopoulos et al. 2009), 
which acts in a paracrine fashion i.e., secreted by non-parenchymal 
cells of liver in response to iron availability (Enns et al. 2013). HJV 
acts as a co-receptor and helps in BMP-receptor complex formation 
(Babitt et al. 2005) and induces phosphorylation of R-SMAD and  
 
SMAD 4, leading to transcription of hepcidin in hepatocytes (Wang et 
al. 2005). 
 
The significance of the pathway in iron metabolism is highlighted by 
the following observations: 
 
1) BMP-6 knockout mice had low hepcidin levels and severe iron 
overload (Meynard et al. 2009) 
 
2)  Mutation in HJV decreases hepcidin levels and causes iron 
overload in juvenile hemochromatosis (Babitt et al. 2006)  
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3) Mice lacking HJV were found to have decreased 
phosphorylated R-SMAD levels (Babitt et al. 2006). 
 
4) Absence of SMAD in hepatocytes leads to decreased hepcidin 
levels and iron overload (Wang et al. 2005). 
 
5) Presence of BMP-RE (response element) I and II in the 
promoter region of the hepcidin gene (Casanovas et al. 2009). 
 
 
 
Matriptase 2: a negative regulator of BMP/HJV/SMAD 
pathway 
 
 HJV is a GPI- (glycophophatidlyinositol) anchored protein (Wang et 
al. 2005) that is highly expressed in liver, heart and skeletal muscles 
(Niederkofler 2005). Matriptase-2, which is a type 2 transmembrane 
protein with serine protease activity, is also highly expressed in 
hepatocyte membrane (Velasco et al. 2002). Its role in iron 
metabolism was demonstrated by finding mutations in TMPRSS6 
gene in iron-resistant iron deficiency anemia (IRIDA) patients 
(Finberg et al. 2008). These patients have severe anemia associated 
with high hepcidin levels. Similar observations were made in mouse 
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models with mutated matriptase 2 (Folgueras et al. 2008). Recently, 
it has been shown that its expression is increased by iron deficiency 
(Du et al. 2008), anemia and hypoxia (Lakhal et al. 2011). The 
matriptase 2 thus induced is said to decrease hepcidin levels by 
inhibiting the BMP/HJV/SMAD pathway. 
 
 
One of the possible mechanisms explained is that matriptase cleaves 
the membrane-bound HJV, which acts as a co- receptor for BMP 
receptor dimer, thereby inhibiting hepcidin transcription via 
BMP/SMAD pathway (Silvestri et al. 2008). But recently, iron and 
BMP-6, which induce hepcidin, were shown to increase expression 
matriptase. Based on these findings, it was suggested that 
matriptase 2 may be involved in fine-tuning of hepcidin synthesis by 
preventing prolonged up regulation of hepcidin (Meynard et al. 2011). 
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Figure 6: Regulation of hepcidin by BMP/HJV/SMAD and HFE-TfR 2  
                signaling  
 
 
 
Source: (Hentze et al. 2010) 
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REGULATION BY ERYTHROID SIGNALS 
 
Erythroid precursors are the major consumers of iron in the body. 
Erythropoietin (EPO) is the main hormone involved in erythropoiesis. 
EPO is synthesized mainly in liver and kidney. It is up-regulated by 
hypoxia associated with anemia. 
  
 Increased erythropoiesis in response to anemia increases the iron 
needs of the precursors. There exists an inverse correlation between 
hepcidin levels and erythropoietic activity. This suggests that some 
mediators are involved in decreasing hepcidin synthesis when there 
is increased erythropoiesis, thereby increasing iron in circulation and 
its availability to erythroid precursors.  
 
 EPO was considered as a possible mediator. EPO administration in 
healthy volunteers was associated  with decreased hepcidin levels 
(Robach et al. 2009). Similar effect was seen when phlebotomy was 
done  to induce erythropoietic drive in healthy volunteers (Ashby et 
al. 2010). However, it was found to have no direct effect on hepcidin 
expression when administered in mice whose bone marrow was 
ablated (Pak et al. 2006). These findings highlight importance of 
erythroid mediators in EPO-induced hepcidin suppression. 
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GDF-15 belongs to the transforming growth factor β (TGF β) super 
family. Its expression is increased during erythroid 
maturation(Tanno et al. 2007). In thalassemia, GDF-15 is expressed 
and secreted in very high quantities. This was found to be 
responsible for low hepcidin level and increased iron absorption seen 
in these patients (Tanno et al. 2007). GDF-15 is thought to decrease 
hepcidin production by inhibiting HJV-BMP pathway.  
 
Twisted gastrulation factor (TWGF) is also increased in the 
thalassaemia mouse model, causing suppression of hepcidin and iron 
overload in them (Tanno et al. 2009). Its  role in humans is not clear. 
 
Erythroferrone (ERFE) is the latest addition to the list of potential 
erythroid mediators. It is produced by erythroblasts in response to 
EPO through Janus kinase/STAT 5 pathway (Kautz and Nemeth, 
2014). Erythroferrone knockout mice failed to suppress hepcidin 
expression on administration of EPO and during stress 
erythropoiesis. Its expression is increased in bone marrow of 
thalassaemia mouse models. However, the observation that ERFE 
deficient mice did not have anemia and had normal hematological 
parameters shows that it is mainly involved in hepcidin suppression 
in stress erythropoiesis. In vitro studies have shown its expression in 
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human erythroblast. Its role in vivo is yet to be studied (Kautz and 
Nemeth, 2014). 
 
All these factors, GDF-15, TWGF and eythroferrone, have been 
shown to mediate expression of hepcidin mainly when there is stress 
erythropoiesis. Erythroid mediators, which regulate hepcidin 
expression under normal steady state erythropoiesis, are still not 
known.  
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Figure 7: Regulation of hepcidin synthesis by erythroid regulators   
                  via inhibition of  BMP/SMAD signaling 
 
 
 
 
Source: (Hentze et al. 2010) 
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INFLAMMATORY CYTOKINES AND HEPCIDIN: 
 
Anemia is associated with inflammatory conditions like inflammatory 
bowel disease (IBD), rheumatoid arthritis, chronic kidney disease 
and also in malignancy. This is referred to as anemia of chronic 
disease (ACD). These patients have hypoferremia and reduced 
transferrin saturation in spite of having normal iron stores. This 
indicates a state of functional iron deficiency during chronic 
inflammation (Adamson 2011) 
 
Hepcidin is an acute phase reactant. Its levels are found to be 
increased by cytokines like interleukin 6 (IL-6) (Nemeth 2003), IL-1 
(Lee et al. 2005)  and decreased by TNFα, which are  produced 
during inflammation (Nemeth 2003). Up-regulation of hepcidin levels, 
leading to sequestration of iron in macrophages is found to be one of 
the factors responsible for anemia in ACD. IL-6 was shown to be the 
main mediator responsible for hepcidin up-regulation during 
inflammation. IL-6 knockout mice failed to increase hepcidin when 
inflammation was induced, while wild-type mice increased hepcidin 
in response to inflammation. Administration of recombinant IL-6 in 
human volunteers increased hepcidin formation, which further 
supported IL 6-mediated hepcidin up-regulation. (Nemeth et al. 
2004) 
39 
 
 
IL-6 acts via JAK/STAT (Janus kinase/signal transducer and 
activator of transcription) pathway to increase hepcidin transcription 
(Wrighting and Andrews 2006). It was observed that IL-6 response 
was blunted in mice with liver-specific SMAD 4 disruption, which 
suggest cross-talk between IL-6-JAK/STAT-3 pathway and 
BMP/HJV/SMAD pathway (Wang et al. 2005).        
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Figure 8: Cytokine induced up regulation of hepcidin by IL 6 via   
                JAK/STAT signaling 
 
 
                              
                                       
 
 
 
 
 
  
Source: (Hentze et al. 2010) 
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IRON, INFLAMMATION AND ANEMIA 
 
Anemia associated with chronic immune activation in conditions like 
chronic infection, inflammation and neoplasm is termed as anemia of 
chronic disease (ACD) or anemia of inflammation (AI). These patients 
usually have hypoferremia, low transferrin saturation and a 
normocytic normochromic blood picture due to functional iron 
deficiency, as iron  is sequestered in its storage form (Weiss and 
Goodnough 2005). 
 
Increased cytokine levels during inflammation are said to play a 
major role in the pathogenesis of ACD at various levels. It affects 
EPO production, erythroid response to EPO, life span of red blood 
cells and iron availability to the erythroid precursors (Means 1995). 
Suppressed EPO expression was observed in isolated rat kidney and 
human hepatoma cell-line due to pro inflammatory cytokines like IL-
1, tumor necrosis factor-α (TNF-α) (Jelkmann 1998). Interferon-γ is 
found to down-regulate EPO receptor in early erythroid progenitors, 
thus inhibiting erythroid differentiation and proliferation in response 
to EPO (Taniguchi et al. 1997; C. Wang, et al. 1995) 
 
Increased hepcidin levels in inflammation in response to IL 6 plays a 
major role in altered iron homeostasis in these patients. Increased 
hepcidin levels results in sequestration of iron in macrophages and 
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also decreases intestinal iron absorption.  Thus, iron deficient 
erythropoiesis occurs with normal body iron stores (Spivak 2002). 
  
Diagnosis of ACD, based only on routinely used iron parameters like 
serum iron, ferritin, transferrin saturation, is difficult. Reduced 
serum iron and transferrin saturation may be similar in ACD and in 
iron deficiency and so they are not useful in differentiating the two 
conditions. Ferritin may be increased or normal as its levels can be 
increased by inflammation so it does not reflect iron stores in ACD. 
sTfR (soluble transferrin receptor) measurement and sTfR/log ferritin 
ratio can be used to differentiate between ACD (ratio < 1), IDA (> 2) 
and also ACD with IDA (>2) (Weiss and Goodnough 2005). 
 
Treating the underlying disease can restore hemoglobin in ACD. But 
in certain conditions with relapses and remissions, recurrent anemia 
is a problem. When ACD is associated with blood loss, there is 
concomitant iron deficiency. In these conditions, along with treating 
underlying disease, treating anemia becomes necessary. Treatment 
usually involves blood transfusions, iron supplementations and 
erythropoietin therapy (Weiss and Goodnough 2005). 
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ULCERATIVE COLITIS AND ANEMIA 
 
Ulcerative colitis, together with Crohn’ disease, is termed as 
inflammatory bowel disease (IBD). Ulcerative colitis (UC) is a disease 
of immune dysregulation of the intestinal mucosa (Longo et al. 2011). 
It is a chronic inflammatory condition with remissions and relapses. 
Ulcerative colitis is said to be more common than Crohn’s in Asian 
countries. Prevalence of UC in India is  not  known due to lack of 
population-based studies (“Indian Society of Gastroenterology 
Consensus on Ulcerative Colitis - Springer” 2014). A study from 
Punjab showed an incidence of 6.02 cases per 100,000 population, 
which was higher than those reported in other Asian countries 
(“Indian Society of Gastroenterology Consensus on Ulcerative Colitis 
- Springer” 2014).    
 
Recurrent anemia is seen in patients with ulcerative colitis. About 
one-third of ulcerative colitis patients develop anemia during the 
course of the disease (Gasche et al. 2004). Several factors contribute 
to anemia in UC. These include iron deficiency due to blood loss 
associated with the disease, anemia due to ongoing inflammation 
and vitamin B12 and folate deficiency, which occur as a result of  
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inadequate dietary supply, inadequate absorption from inflamed 
ileum or due to drug interaction with folate metabolism (Schreiber 
and Wedel 1997).   
 
Hepcidin levels are known to be increased in anemia of chronic 
disease. However, hepcidin levels found to be lower in patients with  
ACD with IDA, which included 4 IBD patients,  when compared to 
patients with ACD (Theurl et al. 2010). Low serum hepcidin with up-
regulation of  Fe-related proteins was reported in the duodenum of 
ulcerative colitis patients (Sukumaran et al. 2014). In another study, 
serum hepcidin was found to be low in IBD patients irrespective of 
presence or absence of iron deficiency anemia (Arnold et al. 2009). In 
a mouse model of colitis, hepcidin concentration were found to be 
low, which was attributed to increase in tumor necrosis alpha, which 
is known to down-regulate hepatic hepcidin expression (Shanmugam 
et al. 2012). The reason for reduced levels of hepcidin in UC is 
currently unknown. One explanation is the fact that hepcidin 
concentration may differ in different types of IBD, which in turn, may 
be the due to the predominant cytokine expressed in that particular 
disease. In any case, determining hepcidin levels and its possible 
negative regulator may help in identifying patients for iron 
supplementation (Shanmugam et al. 2012). 
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Growth Differentiation Factors 15 (GDF15) 
 
 
Growth differentiation factor 15(GDF-15) is also known as 
macrophage inhibitory cytokine 1 (MIC-1).  It belongs to to the TGF-β 
super family (Bootcov et al. 1997). It was first discovered in activated 
macrophages and is said to play role in inhibition of inflammation. 
Structurally, GDF-15 is a 25kDa dimeric secretory protein, with 2 
disulfide bonds  It is mainly expressed in the placenta and in 
maturing erythroblasts (Bootcov et al. 1997).  
 
The role of GDF-15 in erythropoiesis was demonstrated by the 
erythroblast transcriptome project (Miller et al. 1999), where 
increased GDF 15 expression was seen in the cultured erythroblasts 
(Tanno, Noel, and Miller 2010). The cultured erythroblasts failed to 
enucleate, which normally occurred in course of maturation of 
erythroblasts. These cells with higher proliferation rate and inability 
to mature were said to reflect state of ineffective erythropoiesis.  
 
Ineffective erythropoiesis is seen in patients with thalassemia, 
congenital dyserythropoietic anemia I (CDA I), refractory anemia with  
ring-sideroblasts (RARS) and pyruvate kinase deficiency (Tamary et 
al. 2008; Ramirez et al. 2009; Tanno et al. 2007; Finkenstedt et al.  
46 
 
2009). Anemia associated with iron overload was shown to be a 
common feature in these diseases. Serum GDF-15 levels were found 
to be higher in these patients when compared to controls (Tamary et 
al. 2008; Ramirez et al. 2009; Finkenstedt et al. 2009; Tanno et al. 
2007). 
 
Thalassemia and CDA I patients have iron overload, which is not 
only transfusion-related but also due to increased intestinal iron 
absorption. This increased iron absorption was attributed to 
decreased levels of the iron-regulatory peptide, hepcidin, observed in 
these patients (Tanno et al. 2007; Tamary et al. 2008). Increased 
GDF-15 levels were observed correlate with the decreased serum 
levels of hepcidin and ferritin. In addition, immunoprecipitation of 
GDF-15 from the sera of patients with thalassemia resulted in loss of 
ability to suppress hepcidin expression.  Therefore, GDF-15 was 
considered to be an erythroid marker, which regulates hepcidin in 
these  patients (Tamary et al. 2008; Tanno et al. 2007). Further in 
vitro studies by Ramirez et al showed the essential role played by 
GDF-15 in maturation of erythroblasts and its dependence on 
erythropoietin (EPO) (Ramirez et al. 2009).  
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Recent evidence has, however, shown conflicting results on the 
physiological and pathophysiological role of GDF-15 as an erythroid 
regulator of hepcidin, both in humans and mice. For example, a 
significant increase in serum GDF-15 was not observed in human 
volunteers who received erythropoietin or in volunteers who 
underwent phlebotomy. In both these cases, an erythropoietic drive 
was present and hepcidin levels were found to be decreased but 
these did not correlate with serum GDF-15 levels (Ashby et al. 2010). 
GDF-15 knock-out mice did not show any significant effect on 
hematological parameters in these mice. Their response to 
phlebotomy, with respect to iron parameters, was similar to that in 
wild type mice (Casanovas et al. 2013). This suggested that GDF-15 
may not be an important erythroid regulator in mice during normal 
erythropoiesis. 
 
In a study by Theurl et al (2010), serum GDF-15 levels were found to 
be elevated in patients with anemia of chronic disease (ACD) and 
those with ACD and iron deficiency anemia (IDA), when compared 
with subjects who had neither condition and those with only IDA. 
However, the levels of GDF-15 did not correlate with serum hepcidin 
levels observed in these patients. But the study included only four 
patients with IBD, who were categorized under ACD/IDA group. As 
correlations between serum GDF-15 and sTfR receptor was observed 
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in ACD with IDA but not in ACD alone, these authors have suggested 
a possible link between serum GDF-15 production and iron 
availability for erythropoiesis, even during inflammation (Theurl et al. 
2010).  
 
Even though animal and human studies have questioned the role of 
GDF-15 in hepcidin expression in normal erythropoiesis and in acute 
response to erythropoietin (Casanovas et al. 2013 Ashby et al. 2010), 
the role of GDF-15 in iron homeostasis in chronic inflammatory 
conditions such as UC has not been adequately studied.   
 
 
In summary, ACD is a common complication in patients with 
ulcerative colitis and its prevalence varies between 6-70%. Hepcidin 
is a major regulator of iron metabolism. Its levels are known to be 
increased in ACD, thus accounting for iron-restricted erythropoiesis 
in these patients (Nemeth et al. 2003). Even though ulcerative colitis 
is a chronic inflammatory condition, low hepcidin levels have also 
been observed in these patients (Sukumaran et al. 2014, Arnold et 
al. 2009). The precise reason why hepcidin is suppressed despite the 
presence of inflammation is not clear. GDF-15 is one of the known 
negative regulators of hepcidin (Tanno et al, 2007). However, it is not 
known whether its levels are increased in patients with ulcerative 
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colitis.  We hypothesized that serum GDF-15 may be increased in 
patients with UC, which may account for low serum hepcidin levels 
that have been observed in these patients. 
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THE STUDY 
 
 
 
  
51 
 
 
 
 
 
HYPOTHESIS 
 
Hepcidin is the central regulator of iron homeostasis. Work done 
previously in the Department of Biochemistry, CMC, Vellore, has 
shown that serum hepcidin levels were decreased in patients with 
ulcerative colitis. Growth differentiation factor-15 (GDF-15) is a 
known negative regulator of hepcidin. It was, thus, hypothesized that 
serum GDF-15 may be increased in patients with UC, which may 
account for the low serum hepcidin levels that have been observed in 
patients with UC. 
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AIM 
 
The aim of the study was to test the hypothesis that serum GDF-15 
levels may be increased in patients with ulcerative colitis (UC) and to 
determine whether it correlates  with haemoglobin and markers of 
iron status (serum iron and ferritin). 
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MATERIALS 
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EQUIPMENTS USED 
  
 Elix and Milli-Q ultrapure water systems (Millipore, USA)  
 Table-top refrigerated centrifuge (MPW R 350, MPW Poland)  
 Microplate reader, model 680 and microplate manager 
software from Bio-Rad laboratories, Inc. (UK). 
 
CHEMICAL AND REAGENTS USED  
 Quantakine ELISA human GDF-15 kit, R&D systems, Inc (MN, 
US). 
     
  Materials in the kit: 
1. GDF-15 microplate:  96-well polystyrene microplate pre-                            
                          coated with monoclonal antibody specific   
                             for human GDF-15 
 
2. GDF-15 conjugate:   Polyclonal anti-GDF-15 antibody,  
                           conjugated with horse-radish   
                            peroxidase 
 
3. GDF-15 standards:  Recombinant human GDF-15 in  
                          buffered protein solution                                                                                                                                    
                            with preservatives (lyophilized) 
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4. Assay diluents RD1-9: Buffered protein solution with  
                              preservatives 
 
5. Calibrator diluent RD5-20: Buffered protein base with     
                                    preservatives 
 
6. Wash buffer concentrate: 25-fold concentrated solution of    
                               buffered surfactant, with   
                                  preservatives 
 
7. Color reagent A: Stabilized hydrogen peroxide  
 
8. Color reagent B: Stabilized chromogen (tetramethylbenzidine) 
 
 
9. Stop solution:  2N sulphuric acid  
          
The kit was stored at 2-8oC.  
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MISCELLANEOUS CONSUMABLES USED 
 
 Glass vacutainer blood collection tubes (BD Biosciences, 
Plymouth, UK) 
 Pipette micro tips (Tarsons Product Pvt Ltd, India). 
 Graduated centrifuge tubes (15 ml and 
25ml)(Tarsons Product Pvt Ltd, India ) 
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METHODS 
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The study was approved by the Institutional Review Board (IRB) of 
Christian Medical College, Vellore, India. 
                                                     
SUBJECTS 
 
Patients diagnosed to have ulcerative colitis (UC) were the subjects of 
the study. These patients were recruited in the Department of 
Gastroenterology, CMC, Vellore, in the colonoscopy clinic, where they 
underwent the procedure as part of their medical management, or in 
the inflammatory bowel disease (IBD) clinic. Inclusion and exclusion 
criteria used for recruitment were as follows:  
 
INCLUSION CRITERIA:  
 
1. Adults aged 19-60 years, of both genders, who had been  
    diagnosed to have ulcerative colitis 
 
2. A diagnosis of ulcerative colitis was based on presence of   
   symptoms of diarrhoea associated with blood and mucus,  
   of more than 2 months’ duration, where an infective  
   etiology had been excluded and where the disease was  
   confirmed by colonoscopy and mucosal biopsy. 
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3. Patients were either on or off treatment and had either   
active or quiescent disease.  
 
EXCLUSION CRITERIA:  
1. Patients with severe ulcerative colitis were excluded. This 
included the presence of toxic mega-colon, more than 6 
bloody stools per day or fever with leukocytosis. 
 
2. History of iron supplementation or treatment with 
erythropoietin  
 
3.  Patients not willing to participate in the study 
 
Once patients met the inclusion and exclusion criteria, informed 
consent was obtained for recruitment into the study and for 
collection of a venous blood sample. Relevant clinical and baseline 
socio demographic information was collected using a proforma 
(Appendix no.3).  
 
 Age and gender-matched non-anemic control subjects were 
recruited from patients in the Department of Gastroenterology, CMC, 
Vellore, who were diagnosed to have dyspepsia. These patients had 
no abnormalities detected on endoscopy.  
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CALCULATION OF SAMPLE SIZE 
 
Sample size was calculated to be 30 cases by using the following 
formula:  
 
𝑛 =
𝑍∝
2
2  𝑠2
𝑑2
             
 
Where,  
 
𝑍∝
2
2= 95% confidence limit  
d = absolute precision of 450  
S = standard deviation calculated from the mean serum GDF-15 
value (SD=1250pg/ml) in patients with ulcerative colitis reported 
from a previous study (Theurl et al, 2010).  
 
However, one set of reagents for estimation of serum GDF-15 was 
sufficient only for 40 samples to be done in duplicate. Since the IRB 
funded the study only to a maximum amount of Rs. 80,000 for 2 
years, it was possible to study only 20 patients with UC and 20 
control subjects in this study. 
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INFORMED CONSENT 
 
           Information sheets were provided to the patients and their relatives, 
which explained the purpose of the study. Oral information regarding 
the study was also given by PI and consent was obtained from the 
patients. The information sheets and consent forms were prepared in 
5 different languages (i.e.  English, Hindi, Telugu, Tamil and 
Bengali). A copy of the English version is provided in Appendix 2. 
Once consent was obtained from patients, a blood sample was 
collected from each. The patients’ socio-demographic details and 
relevant patient history regarding disease, medication and co-morbid 
conditions were obtained. The proforma used for collecting history 
and data is included in Appendix-3. Results of some hematological 
parameters such as hemoglobin, mean corpuscular volume (MCV), 
C-reactive protein (CRP) and reports of colonoscopy and biopsy 
samples were obtained from hospital records of patients. 
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COLLECTION OF SAMPLES 
 
 
Venous blood samples were collected in vacutainer tubes, using 
aseptic precautions. The sample was allowed to clot and then 
subjected to centrifugation, using a table-top centrifuge at 1200g for 
10 minutes. The serum obtained was divided into several aliquots 
and stored at -70o C. These samples were used for estimation of 
serum C-reactive protein (CRP), iron, ferritin and GDF-15.  
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ESTIMATION OF C-REACTIVE PROTEIN 
 
 
 
Serum CRP estimation was done in the Department of Microbiology, 
CMC, Vellore, where it is offered as a routine test.  
 
 Analyzer used: 
 
Nephelometer -BN Prospec, Siemens GmbH, Marburg, Germany 
 
 
Principle of the assay:  
 
This consists of an in-vitro test for quantitative estimation of CRP in 
human serum by particle-enhanced nephelometry. 
 
The method involved formation of aggregates due to interaction 
between monoclonal antibodies against human CRP (coated on 
polystyrene beads) and CRP in a serum sample. The aggregates 
formed scattered light passed through it. The intensity of scattered 
light was measured. This was proportional to the concentration of 
CRP in the serum.                  
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ESTIMATION OF SERUM IRON 
 
Estimation of serum iron was done in the Department of Clinical 
Biochemistry, CMC, Vellore, where it is offered as a routine test.  
 
Analyzer: 
 
Roche Modular P, clinical chemistry auto analyzer, Germany. 
 
 
 
 
 Principle of the assay: 
 
 
Estimation of iron was done by a colorimetric assay. Iron was 
released from transferrin in serum, at acidic pH. Free ferric iron was 
then reduced by ascorbate to its ferrous form. Ferrous iron then 
reacted with ferrozine to form a coloured complex.  The colour that 
developed was measured photometrically at 560nm. The intensity of 
colour developed was directly proportional to the concentration of 
iron in the sample. 
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ESTIMATION OF SERUM FERRITIN 
 
Estimation of serum ferritin was done in the Department of Clinical 
Biochemistry, CMC, Vellore, where it is offered as a routine test.  
 
Analyzer:  
Siemens, ADVIA Centaur system Xpi, UK   
 
Principle: 
Ferritin was measured by a 2-site sandwich immune assay, using a 
chemiluminometric method. Two antibodies directed against human 
ferritin were used. The first antibody was an acridinium ester-labeled 
polyclonal goat anti-ferritin antibody, which was in a liquid phase. 
The second antibody was a monoclonal mouse anti-ferritin antibody, 
which was covalently linked to paramagnetic particles and was in a 
solid phase. Both antibodies were added simultaneously to the 
sample and incubated for 7.5 minutes at 370C. The ferritin in the 
sample reacted with both the antibodies to form a complex, in which 
ferritin was sandwiched between the 2 antibodies. The immune 
complex formed was immobilized in the cuvette with help of a 
magnetic field, which interacted with paramagnetic particles. Excess 
antibodies and antigen were removed by washing. Acid and base 
reagents were added to the cuvette to initiate a chemiluminescent 
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reaction. Relative light units were measured by the detector; this was 
directly proportional to concentration of ferritin in the sample. 
 
                     
ESTIMATION OF SERUM GDF-15 
 
 
Serum GDF-15 levels were estimated by an enzyme-linked 
immunosorbent assay (ELISA), using commercially available reagents 
(Quantakine ELISA kit R & D Systems, Inc. Minneapolis, MN). 
 
 
Principle of the assay: 
 
It was a quantitative solid phase sandwich enzyme immunoassay. It 
contained a 96-well polystyrene microplate, pre-coated with a 
monoclonal antibody specific for human GDF-15. When a 
sample/standard was added to a well, GDF-15 in the 
sample/standard bound to the antibody pre-coated in the well. This 
formed an antigen-antibody immobilized complex. The unbound 
GDF-15 in each sample was removed by washing with wash buffer. A 
polyclonal anti-GDF-15 antibody, conjugated with horseradish 
peroxidase, was then added to each well. The GDF-15 was 
sandwiched between the antibody pre-coated on the plate and the 
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conjugated antibody.  The unbound conjugated antibody was 
removed by washing with wash buffer.  
 
After this, the substrate solution (hydrogen peroxide and 
tetramethylbenzidine) were added. A colour developed in the well due 
to the action of the enzyme on the substrate. The intensity of colour 
developed was directly proportional to the concentration of GDF-15 
in the sample/standard. The development of colour was stopped by 
adding the stop solution. The intensity of the colour that developed 
subsequently was measured. 
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Steps involved in estimation of serum GDF-15, using Quantakine 
ELISA kit, R & D systems.  
 
                           
 
 Source: 
rndsystems.com//product_detail_objectname_quantikineelisaassayp
rinciple.asx 
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PREPARATION OF REAGENTS: 
All reagents were brought to room temperature before use. 
 
Wash buffer:  350ml of wash buffer was prepared by diluting 14ml 
of concentrated wash buffer in 336 ml deionized water. 
 
Substrate solution:  Colour reagent A (11ml) and colour reagent 
B (11ml) were mixed to prepare 22ml of substrate solution. The 
solution was used within 15 minutes of preparation. 
 
GDF-15 standards:  
 
Stock standard: GDF-15 standard solution was reconstituted with 
1ml of calibrator diluent, RD5-20, to prepare a stock solution of 
15,000pg/ml. The stock standard was mixed well and allowed to 
stand for 15 minutes, before preparing serially diluted standards. 
900µl of calibrator diluent, RD5-20, was added to a 1500pg/mL (S7) 
tube. 500µl of calibrator diluent, RD5-20, was pipetted into each 
tube labeled S1 to S6. Serial dilutions were done, using the stock 
standard as shown in the figure below (the figure below is from the 
instruction sheet provided by the manufacturer). 
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 The 1,500pg/ml standard served as the highest standard and the 
calibrator diluent, RD5-20, as the zero standard or blank. 
 
  
Sample preparation: 
 
A 5-fold dilution of each sample was done. For this, 50µl of a sample 
was diluted with 200µl of calibrator diluent, RD5-20.  
                   
  
 
 
 
 
  S7                  S6              S5                 S4                  S3                 S2                 S1             
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ASSAY PROCEDURE:  
 
Step 1:  100µl of assay diluent RD1-9 was added to each well. 
 
Step 2:  50µl of standard or diluted sample was added to a well.   
              The micro-plate was covered with adhesive tape provided  
              in the ELISA kit for this purpose, and incubated for 2  
             hours at room temperature  
 
Step 3: Next, 300µl of wash buffer was added to each well. This   
            was done using a multichannel pipette. The wash buffer   
           was removed. The washing was repeated 4 times. The plate  
            was then inverted and blotted against a clean paper towel  
           to remove all the fluid.                       
.               
Step 4: 200µl of GDF-15 conjugate was added to each well. The  
            plate was covered with   adhesive tape provided in the kit  
            and incubated for 1hour at   room temperature. 
 
Step 5:   The wells were then washed as described in step 3. 
 
Step 6: 200µl of freshly prepared substrate solution was added to  
          each well. The plate was incubated in the dark for 30  
         minutes, at room temperature.  
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Step 7: 50µl of stop solution was added to each well .The colour   
            change from blue to yellow was observed. 
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Step 8: The optical density (OD) of the solution in each well was    
             determined using a micro plate reader. This was done   
             within 30 minutes after addition of the stop solution.  
             Readings were   taken at 450nm.  A correction wavelength  
             540nm was used to correct for optical imperfection of  
             plate. OD obtained at 540nm was subtracted from OD at     
             450nm automatically by the software, before the final   
             OD was reported. 
 
The standards and all samples were estimated in duplicates. The 
average of the 2 OD values obtained was used to calculate the 
concentration of GDF-15 in each sample.  
      
  
 Calculation of results: 
 
A standard curve was generated by 4 parametric logistic curve (4 PL) 
curve fit, using software of the microplate reader.          
  
The concentration of GDF-15 in each sample was obtained using 
the microplate reader software.  
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STATISTICAL ANALYSIS 
 
Statistical analysis of data was done using the Statistical Package for 
Social Scientists (SPSS), version 17. Distribution of values of 
parameters studied was checked for normality, using Shapiro-Wilk 
test. Data were compared between the 2 groups, using unpaired T- 
test for normally distributed data and Mann- Whitney U test for data 
that were not normally distributed. Correlation analysis was done 
using Pearson’s correlation coefficient for normally distributed data 
and Spearman’s correlation coefficient for data with skewed 
distribution.  
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RESULTS 
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ANALYSIS OF DISTRIBUTION OF DATA: 
 
Values for age, haemoglobin, mean corpuscular volume (MCV) and 
serum iron were found to be normally distributed. Values for serum 
GDF-15, ferritin and C-reactive protein (CRP) were found to have 
skewed distributions.  
 
 
CHARACTERISTICS OF SUBJECTS IN THE 
STUDY 
 
A total of 40 participants were recruited into the study. Twenty 
patients diagnosed to have ulcerative colitis (UC) served as cases. 
Twenty age and gender-matched patients, with no evidence of 
anaemia (hemoglobin equal to or more than l3gm/dl in males and 
equal to or more than 12gm/dl in females) or inflammation (serum 
CRP less than 6 mg/L) served as control subjects. 
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The characteristics of the subjects in the study are shown in Table 1. 
Table 1: 
 
 
Characteristic 
  
      
 Patients with 
 ulcerative colitis           
                 
                   
                    
        
       Control patients   
 
 
 
Number  of patients 
 
              
               20 
 
                   
                      20 
 
Males/females 
                         
             13/7 
                         
                     13/7 
Mean age (years)  
( + SD) 
          40.45 (8.17) 
 
 
                39.75 (7.55)    
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HAEMATOLOGICAL PARAMETERS 
 
The haematological parameters estimated were levels of haemoglobin 
and mean corpuscular volume. The results for these are shown in 
Figures 1 and 2.  
 
Figure 1: Haemoglobin levels 
 
Data are shown as means (± SD). Data were analysed by unpaired T- 
test. *p value < 0.05, when compared with control data 
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Haemoglobin levels were significantly lower in patients with 
ulcerative colitis than in control patients. Among the 20 patients 
with ulcerative colitis, 12 were found to be anaemic (hemoglobin 
levels less than l3gm/dl in males and less than 12gm/dl in females).  
 
Figure 2: Mean corpuscular volume (MCV) 
 
 
          Data are shown as mean (±SD) and were analysed by   
unpaired T-test. 
 
 Mean corpuscular volumes (MCV) in the 2 groups were not 
significantly different from one another.   
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.                               
IRON-RELATED PARAMETERS 
 
Figure 3: Serum iron levels 
 
 
Data are shown as mean (±SD) and were analysed by unpaired T- 
test.   
 
Serum iron levels in the 2 groups were not significantly different from 
one another.  
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Figure 4: Serum ferritin levels 
 
 
 
Data are shown as box and whisker plots, with the quartiles and 
medians shown. The outliers in each group are shown as numbered 
dots. Data were analysed by Mann – Whitney U test.   
 
Serum ferritin levels tended to be lower in patients with UC, but the 
decrease was not statistically significant (p = 0.09).  
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MARKER OF INFLAMMATION 
 
Figure 5: Serum C-reactive protein 
 
 
 
 
Data are shown as box and whisker plots, showing quartiles and 
medians. Outliers in each group are shown as numbered dots. Data 
were analysed by Mann – Whitney U test. 
 
Serum CRP levels tended to be higher in patients with UC; however, 
the increase was not statistically significant. 
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SERUM GDF 15 LEVELS 
Serum GDF-15 levels in patients with ulcerative colitis (n= 20) and 
control patients (n=20) were estimated by ELISA. 
 
A standard curve for GDF-15 was generated using the Bio-Rad 
Laboratories micro-plate manager software.  The concentration of 
GDF-15 in each sample was obtained from this curve.  
Figure 6. Standard curve for GDF-15 
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Figure 7: Serum levels of GDF-15 in subjects 
 
 
 
Data are shown as box and whisker plots, showing quartiles and 
medians.  Outliers in each group are shown as numbered dots. Data 
were analysed using Mann-Whitney U test. * indicates p value < 0.05 
when compared to controls.    
 
Serum GDF-15 levels were found to be significantly higher in 
patients with UC. 
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CORRELATION ANALYSIS 
Correlational analysis was done with the total number of 40 patients 
and also separately for the control subjects and for those with UC.  
 
Table 2: Results of analysis done with the total number of 40 
patients 
 
 
   
Correlation 
coefficient  
 
 
  p 
value 
 
 
  
Using total data (UC + 
control) (n=40) 
 
 
Serum GDF-15  vs 
 
Age 
 
Haemoglobin 
 
 
Haemoglobin vs 
 
Serum iron  
 
Serum ferritin  
 
 
Serum ferritin vs 
 
Serum iron 
   
 
   
  
 
 
 
0.446* 
 
-0.379* 
 
    
 
 
0.462* 
 
0.490* 
 
 
 
 
0.622* 
 
 
 
    
      
       
      
0.004 
       
0.016 
 
 
 
        
0.003 
 
        
0.001 
 
 
 
 0.00 
 
 
 
 
 
 
 
 
 
 
 
Analysis done by Spearman’s or Pearson’s correlation test, as 
appropriate.* indicates correlation is significant at the 0.05 level (2-
tailed).  
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Only significant correlations have been shown. There were no other 
statistically significant correlations among any of the other 
parameters.  
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Table 3: Results of correlation analysis done in patients with UC  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Correlation analysis was done by Spearman's or Pearson’s 
correlation test, as appropriate. * indicates correlation is significant 
at the 0.05 level (2-tailed).  
 
There were no other statistically significant correlations among any 
of the other parameters.      
 
 
 
 
 
  
Correlation 
coefficient  
 
 
p value 
 
Patients with UC 
(n=20) 
 
  
Serum GDF-15 vs 
 
Age  
 
MCV (n=15) 
 
Serum ferritin  
 
Haemoglobin 
 
 
Serum iron vs 
 
Haemoglobin 
 
Serum ferritin  
 
 
 
 
 
 
  
 
 
 
0.416 
 
0.55* 
 
0.391 
 
- 0.375 
 
 
 
 
0.587* 
 
0.612* 
 
 
 
 
     
  
 
  0.068 
     
  0.034 
 
  0.088 
 
  0.104 
 
  
     
  
 0.006 
     
 0.004    
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Table 4: Results of correlation analysis done in control patients. 
  
 
                                 
 
 
 
 
 
 
 
Correlation analysis was done by Spearman's or Pearson’s 
correlation test, as appropriate. * indicates correlation is significant 
at the 0.05 level (2-tailed).  
 
There were no other statistically significant correlations among any 
of the other parameters.       
                        
 
 
 
 
  
Correlation 
coefficient  
 
 
p value 
 
 
Control patients 
(n=20) 
 
Serum GDF 15  vs 
 
 Age  
 
MCV(n=14) 
 
 
Serum ferritin Vs 
 
Haemoglobin 
 
Serum iron  
  
 
 
 
 
 
0.569* 
 
-0.616* 
 
 
 
 
0.655* 
 
0.576* 
          
 
   
  
    
 
0.009 
 
0.019 
 
        
  
 
0.002 
 
 0.008 
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SUMMARY OF FINDINGS 
 
1. Haemoglobin levels were found to be significantly lower in 
patients with ulcerative colitis, when compared with control 
patients.  
 
2. Serum growth differentiation factor 15 (GDF-15) levels were 
found to be significantly higher in patients with ulcerative 
colitis, when compared with control patients. 
 
3. When all the subjects in the study were considered together, 
levels of serum GDF-15 correlated positively with age and 
negatively with haemoglobin. Haemoglobin and serum levels 
iron and ferritin bore significant positive correlations with one 
another.  
 
4. In patients with UC, a significant positive correlation was seen 
between serum GDF-15 and MCV values. There was also a 
tendency for GDF-15 to correlate positively with age and serum 
ferritin and negatively with haemoglobin levels. Haemoglobin 
and serum levels of iron and ferritin bore significant positive 
correlations with one another. 
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5. In control patients, serum GDF-15 levels correlated positively 
with age and negatively with MCV. Serum ferritin levels 
correlated positively with haemoglobin and serum iron levels.  
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DISCUSSION 
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Anemia is a common complication in patients with ulcerative colitis 
(UC). Its prevalence has been estimated to vary between 6 and 70% 
in patients with IBD (Ott et al. 2012). The anemia that develops in 
patients with UC is of complex etiology; it may be due to 
inflammation associated with the condition or due to iron deficiency 
caused   by blood loss in stools, or both (Schreiber and Wedel 1997). 
However, despite the prevalence of anemia in those with IBD, 
resulting in the quality of life being affected, the condition is often 
under-treated in clinical practice (Ott et al. 2012). 
 
Hepcidin plays a major role in iron homeostasis (Ganz. 2003).  Its 
levels are increased in inflammatory states (Nemeth et al, 2003; Lee 
et al. 2005).  It was expected that, given the known effect of pro-
inflammatory cytokines such as IL-6 in inducing hepcidin, levels of 
hepcidin would be elevated in those with IBD.  
 
However, an earlier study done in the Department of Biochemistry at 
CMC, Vellore, found that serum hepcidin levels were significantly 
decreased in patients with ulcerative colitis (Sukumaran et al. 2014). 
This was an unexpected finding.  In order to account for this, the 
authors have suggested that that the presence of anemia in these 
patients was likely to be the reason that caused down-regulation of 
hepcidin. Thus, it seemed to confirm an earlier postulate that, when 
anemia and inflammation co-exist, the effect of the former on 
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hepcidin suppression predominates over that of the latter to induce it 
(Sukumaran et al. 2014). A similar observation of low serum 
hepcidin levels has been reported earlier in patients with IBD; this 
was found to be so, irrespective of the presence or absence of iron 
deficiency anemia  (Arnold et al. 2009). A mouse model of colitis has 
also been shown to have low hepcidin expression; this was attributed 
to increased TNF-α levels, which is known to down-regulate hepcidin  
(Shanmugam et al. 2012). 
 
The finding of low serum hepcidin in patients in patients with UC 
raised the question of why levels were low in this condition, despite 
the presence of inflammation. There are several known negative 
regulators of hepcidin. GDF-15 is one of them. Very high levels of 
GDF 15 have been reported in patients with ineffective erythropoiesis 
associated with conditions such as thalassemia and congenital 
dyserythropoietic anemia I, where it was shown to down-regulate 
hepcidin expression (Tanno et al 2007, Tamary et al. 2008).  Its 
levels have also been shown to be increased in anemia of  
inflammation and iron deficiency (Theurl et al. 2010).  
 
Based on the observations of Sukumaran et al (2014), it was 
hypothesized that the low levels of hepcidin seen in patients with 
ulcerative colitis may be a result of increased serum GDF-15 levels. 
It was to test this hypothesis that the present study was carried out. 
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The results show that GDF-15 levels were, indeed, higher in patients 
with UC.  
 
Sixty percent of the patients with UC in the present study were found 
to be anemic. The levels of hemoglobin in patients with UC were 
significantly lower than in control patients. Serum iron and ferritin 
levels were measured to assess iron status of the subjects. Serum 
ferritin levels tended to be lower in patients with UC (with a median 
value of28.85 µg/L; range: 3.6-249 µg/L) than in controls (median 
value of 54.1 µg/L; range: 4.7- 465 µg/L) (p = 0.08), suggesting a 
state of iron deficiency. Serum iron levels were, however, not 
significantly different.  
 
It would be difficult to determine whether the patients in the present 
study had anemia of inflammation or iron deficiency or a 
combination of the 2. This is a common dilemma in clinical practice. 
The lower ferritin levels tend to indicate that a state of iron deficiency 
may exist.   This is consistent with the clinical finding that 14 
patients out of 20 patient with UC had blood loss in stools at the 
time of recruitment.  Most of these patients showed signs of 
inflammation on colonoscopy and in the mucosal biopsy. However, 
serum CRP levels, a marker of systemic inflammation, were not 
elevated in these patients. This may be the result of response to 
treatment. Measurement of additional parameters, such as soluble 
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transferrin receptor (sTfR) (which is not affected by inflammation) 
and calculation of  the sTfR/log ferritin ratio would have been helpful 
in differentiating anemia due to inflammation and that due to iron 
deficiency (Skikne 2008). However, it was not possible to measure 
sTfR levels in these patients’ samples, due to financial constraints.  
 
Correlation analysis showed significant negative correlation between 
serum GDF-15 and hemoglobin, when all the patients in the study 
(both control patients and those with UC) were considered together. 
This relationship did not hold good when the 2 groups were 
considered separately.  These findings are similar to those of 
observed by Theurl et al (2010). In the present study, MCV values 
and GDF-15 levels were positively correlated in patients with UC and 
negatively in control patients. The reasons for this observation are 
not clear. Studying a larger sample of patients may help better 
elucidate the relationships involved. 
 
 The  finding that there was no significant difference in CRP levels 
between patient with UC and those in the control group differs from 
those of Sukumaran et al (2014) and Theurl et al (2010).  This 
indicates decreased inflammatory activity in patients with UC in this 
study, which may be an indication of their improvement due to the 
treatment they were receiving. However, it has also been shown that 
CRP responses in patients with UC can be poor, in  spite of active 
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inflammation (Vermeire et al, 2004). Correlation analysis did not 
show any significant association between serum CRP and GDF-15 
levels.  It may have been useful to have measured serum interleukin 
6 (IL--6) in these patients, as it is known that IL 6 is the main pro-
inflammatory cytokine, which is shown to up-regulate hepcidin 
(Nemeth et al, 2003). However, once again, financial constraints 
precluded estimation of serum IL-6 in these patients.  
 
In the present study, patients with ulcerative colitis had higher levels 
of serum GDF 15 when compared to controls. This was consistent 
with higher serum GDF-15 levels reported by Theurl et al (2010) in 
patients with ACD and in those with ACD with IDA.  
 
It was not possible to estimate serum hepcidin levels in these 
patients, once again due to financial constraints. It would have been 
useful to do this, in order to be able to correlate serum levels of GDF-
15 and hepcidin in these patients. It is hoped that it will be possible 
to do this at a later time point. The median serum GDF-15 levels in 
patients with UC in this study was 849 pg/ml (range: 385-
2043pg/ml); such levels were found to be lower than levels that have 
been reported in thalassemia mean (66,000 ± 9,600 pg/ml) (Tanno et 
al, 2007; Tamary et al. 2008). Increase in GDF-15 levels in 
thalassemia is shown to be due to increased proliferation and 
apoptosis of erythroid cells, due to an imbalance in the synthesis of 
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alpha and beta chains of hemoglobin (Tanno et al 2007). In patients 
with UC, it may be possible that there is an increase in erythroid 
activity in response to anemia; such an effect may account for raised 
GDF-15 levels. Theurl et al (2010) found significant correlations 
between serum levels of GDF-15 and sTfR and have suggested that 
increases in serum GDF-15 levels may reflect increased erythroid 
activity, even in presence of inflammation in patients with IDA/ACD. 
Serum erythropoietin and sTfR levels were not measured in the 
present study; hence, it was not possible to study possible 
associations between GDF-15 and erythropoietic drive and erythroid 
activity.   
 
Interestingly, a positive correlation was found between serum GDF-
15 levels and age, in control patients alone and also when all the 
subjects were considered together. There was a similar trend in 
patients with UC as well (r =0.416; p =0.06).  Such a finding has 
been reported earlier by Wiklund et al (2010), who have shown that   
increases in GDF-15 levels occurred with increasing age. Such an 
increase has been suggested to  be due to increase in p53 levels 
associated with aging, with  p53 known to up-regulate GDF-15 
expression (Wiklund et al. 2010). 
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CONCLUSION 
 
In conclusion, serum GDF-15 levels were found to be significantly 
increased in patients with ulcerative colitis. These patients also had 
significantly lower levels of hemoglobin. Increases in GDF-15 may 
reflect increased erythropoiesis in these patients in response to 
anemia. This would, in turn, down-regulate hepcidin levels, an effect 
that has been reported in an earlier study from the department. More 
detailed studies involving estimation of serum hepcidin, sTfR, 
erythropoietin and other iron-related parameters in these patients 
would help elucidate the relationships involved further.  
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LIMITATIONS OF THE STUDY 
 
 
 
 
 The sample size for the study was small.  
 
Due to financial constraints, several related parameters such as 
serum hepcidin, sTfR, erythropoietin and IL-6 could not be 
estimated. Measurement of these parameters would have provided 
information that may have contributed to elucidating the events 
involved and also in differentiating patients with anemia of 
inflammation or iron deficiency anemia 
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FUTURE DIRECTIONS 
 
 
 
Estimation of the following parameters need to be carried out for a 
better understanding of the events involved in the pathogenesis of 
anemia in patients with  ulcerative colitis: 
 
 Serum hepcidin levels  
 Serum sTfR and erythropoietin 
 Serum IL 6 and serum TNF α levels, which are known to be 
involved in ulcerative colitis, and also known to alter hepcidin 
expression. 
 
Measurement of these parameters could help in better 
understanding of iron metabolism and anemia in patients with 
ulcerative colitis.  
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APPENDIX 2 
                    CONSENT FORM IN ENGLISH 
 
      SERUM GDF-15(GROWTH DIFFERENTIATION FACTOR 15)   
         LEVELS IN PATIENTS   WITH ULCERATIVE COLITIS 
                 INFORMATION SHEET FOR PATIENTS  
 
The Department of Biochemistry at Christian Medical College, 
Vellore, in association with the Department of Gastroenterology is 
carrying out a study to understand changes that occur in the way 
iron is handled in the body in patients with ulcerative colitis. 
Because of these changes, patients with ulcerative colitis often 
develop anemia. This affects the quality of life in these patients. How 
and why anemia develops is not completely understood. We would 
like to study this problem to gain a better understanding of it. This 
knowledge may help doctors deal more effectively with the problem. 
In order to do this study, we will need 10 ml of blood. We would like 
to ask you if you are willing to provide 10 ml of blood for this 
purpose.  
You may not directly benefit from the study. However, if you are 
willing to participate in the study and provide a blood sample, it will 
help us to better understand how anemia develops in ulcerative 
colitis and may help, in the future, to improve treatment for the 
condition.  
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The blood sample collected will be used only for research purposes. If 
there is any sample remaining after this study is completed, we 
would like to request you for permission to store the blood and used 
for future similar studies. Collection of this sample of blood will not 
cause harm to your health in any foreseeable manner. The medical 
information you give us will be kept confidential.  
If you do not wish to give the blood sample requested, you are free to 
say so. It will not affect the treatment you will receive in the hospital. 
If you have any further queries, please contact me on the number 
provided below.  
Dr Chinmai Jagadish  
Post graduate Demonstrator  
Department of Biochemistry  
Christian Medical College, Vellore -632002  
Contact number: 95566736587  
 
Dr Molly Jacob  
Professor  
Department of Biochemistry  
Christian Medical College, Vellore -632002  
Dr A. J. Joseph  
Professor  
Department of Gastroenterology  
Christian Medical College, Vellore -63200  
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INFORMED CONSENT DOCUMENT FOR SAMPLE OF BLOOD  
 
Dr. Chinmai Jagadish has explained to me the details of the study 
proposed. I have understood what has been said including the 
following 
  
1. If I agree to participate in this study, a blood sample (10 ml) will be 
collected from me.  
 
2. This will not affect my health in any foreseeable way.  
 
3. The blood sample will be used only for research purposes. If there 
is any sample remaining after this study is completed, the sample 
will be stored and may be used for future studies on ulcerative colitis 
and iron.  
 
I am willing to donate 10ml of blood voluntarily without any coercion 
from investigators of this project.  
 
Signature of donor                                         Signature of 
investigator  
Name of the donor:  
Signature of witness:  
Date: 
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APPENDIX – 3 
             PROFORMA USED TO OBTAIN INFORMATION ON                   
                  CLINICAL PROFILE OF THE PATIENT  
 
SERUM GROWTH DIFFRENTIATION FACTOR 15 IN PATIENTS      
                       WITH ULCERATIVE COLITIS 
 
                                     Proforma  
Name: 
 Hosp no:  
Age:  
Gender:  
Address:  
Presenting complaint:  
History  
Duration of the disease:  
Date when diagnosis of UC made:  
Number of stools/day currently:  
Presence of blood in the stool currently:  
Fever:  
Any other relevant complaints:  
 
Past history:  
Similar complaints in past:  
Other diseases:  
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Surgical history (eg, appendectomy):  
 
Personal history:  
Alcohol intake:  
Smoking:  
Menstrual history:  
 
Drug history: 
Drugs for anemia:  
Iron supplements  
EPO: 
Any other drugs used: 
Investigations:  
Hb:  
Serum iron:  
Serum ferritin:  
CRP:  
Serum protein and albumin:  
Stool examination:  
Parasites:  
Colonoscopy findings:  
Upper GI endoscopy findings:  
Biopsy reports: 
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